FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017629478> ?p ?o ?g. }

• W2017629478 endingPage "448" @default.
• W2017629478 startingPage "443" @default.
• W2017629478 abstract "Objective To define the safety [dose limiting toxicity (DLT)] and recommended phase II dose of the combination of sorafenib plus gemcitabine and capecitabine for advanced renal cell carcinoma (RCC). Methods In this phase I dose-escalation study, cohorts of 3 to 6 patients with metastatic RCC received sorafenib (200 or 400 mg po BID), gemcitabine (750 or 1000 mg/m2 intravenous on days 1 and 8), and capecitabine (415 or 622 mg/m2 po BID days 1–14) every 21 days using a standard 3+3 design. Results Fifteen patients with advanced RCC (93% with clear cell histology and 87% treatment naive) received treatment. The recommended phase II doses for the combination were sorafenib 200 mg/m2 BID continuously plus gemcitabine 750 mg/m2 intravenous days 1 and 8 and capecitabine 415 mg/m2 BID days 1 to 14, every 21 days. Of the 15 patients, 3 developed dose-limiting hand-foot syndrome during the first 2 cycles; 2 additional DLT's were grade 3 mucositis and transaminase elevation. Four of 14 evaluable patients had a partial response by response evaluation criteria in solid tumors (29%; 95% confidence interval (CI): 8, 58%). Median progression-free survival was 7.5 months (95% CI–0, 18.7), and median overall survival has not been reached at a median follow-up of 28.8 months. The median number of treatment cycles given was 7 (range, 2–38+). Conclusions The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome. Antitumor activity was observed leading to an ongoing phase II trial." @default.
• W2017629478 created "2016-06-24" @default.
• W2017629478 creator A5004714469 @default.
• W2017629478 creator A5007663088 @default.
• W2017629478 creator A5027165899 @default.
• W2017629478 creator A5028538472 @default.
• W2017629478 creator A5055404518 @default.
• W2017629478 creator A5059711739 @default.
• W2017629478 creator A5065354635 @default.
• W2017629478 creator A5083206599 @default.
• W2017629478 creator A5083920381 @default.
• W2017629478 creator A5061047866 @default.
• W2017629478 creator A5090321428 @default.
• W2017629478 date "2011-10-01" @default.
• W2017629478 modified "2023-09-27" @default.
• W2017629478 title "A Phase I Trial of Sorafenib Plus Gemcitabine and Capecitabine for Patients With Advanced Renal Cell Carcinoma" @default.
• W2017629478 cites W1570491737 @default.
• W2017629478 cites W1603230122 @default.
• W2017629478 cites W1942932003 @default.
• W2017629478 cites W1984400406 @default.
• W2017629478 cites W1986910634 @default.
• W2017629478 cites W1994276424 @default.
• W2017629478 cites W1999966467 @default.
• W2017629478 cites W2008565103 @default.
• W2017629478 cites W2012852444 @default.
• W2017629478 cites W2016220220 @default.
• W2017629478 cites W2059860479 @default.
• W2017629478 cites W2062302016 @default.
• W2017629478 cites W2073311244 @default.
• W2017629478 cites W2125962958 @default.
• W2017629478 cites W2126275851 @default.
• W2017629478 cites W2127410521 @default.
• W2017629478 cites W2139248078 @default.
• W2017629478 cites W2143813821 @default.
• W2017629478 cites W2145835533 @default.
• W2017629478 cites W2147186814 @default.
• W2017629478 cites W2149026055 @default.
• W2017629478 cites W2157769714 @default.
• W2017629478 doi "https://doi.org/10.1097/coc.0b013e3181e9c0d7" @default.
• W2017629478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20881475" @default.
• W2017629478 hasPublicationYear "2011" @default.
• W2017629478 type Work @default.
• W2017629478 sameAs 2017629478 @default.
• W2017629478 citedByCount "9" @default.
• W2017629478 countsByYear W20176294782014 @default.
• W2017629478 countsByYear W20176294782015 @default.
• W2017629478 countsByYear W20176294782016 @default.
• W2017629478 countsByYear W20176294782017 @default.
• W2017629478 countsByYear W20176294782018 @default.
• W2017629478 countsByYear W20176294782019 @default.
• W2017629478 countsByYear W20176294782020 @default.
• W2017629478 crossrefType "journal-article" @default.
• W2017629478 hasAuthorship W2017629478A5004714469 @default.
• W2017629478 hasAuthorship W2017629478A5007663088 @default.
• W2017629478 hasAuthorship W2017629478A5027165899 @default.
• W2017629478 hasAuthorship W2017629478A5028538472 @default.
• W2017629478 hasAuthorship W2017629478A5055404518 @default.
• W2017629478 hasAuthorship W2017629478A5059711739 @default.
• W2017629478 hasAuthorship W2017629478A5061047866 @default.
• W2017629478 hasAuthorship W2017629478A5065354635 @default.
• W2017629478 hasAuthorship W2017629478A5083206599 @default.
• W2017629478 hasAuthorship W2017629478A5083920381 @default.
• W2017629478 hasAuthorship W2017629478A5090321428 @default.
• W2017629478 hasConcept C121608353 @default.
• W2017629478 hasConcept C126322002 @default.
• W2017629478 hasConcept C126894567 @default.
• W2017629478 hasConcept C141071460 @default.
• W2017629478 hasConcept C143998085 @default.
• W2017629478 hasConcept C2776694085 @default.
• W2017629478 hasConcept C2777472916 @default.
• W2017629478 hasConcept C2777909004 @default.
• W2017629478 hasConcept C2778019345 @default.
• W2017629478 hasConcept C2778496288 @default.
• W2017629478 hasConcept C2778695046 @default.
• W2017629478 hasConcept C2780258809 @default.
• W2017629478 hasConcept C29730261 @default.
• W2017629478 hasConcept C526805850 @default.
• W2017629478 hasConcept C71924100 @default.
• W2017629478 hasConcept C90924648 @default.
• W2017629478 hasConceptScore W2017629478C121608353 @default.
• W2017629478 hasConceptScore W2017629478C126322002 @default.
• W2017629478 hasConceptScore W2017629478C126894567 @default.
• W2017629478 hasConceptScore W2017629478C141071460 @default.
• W2017629478 hasConceptScore W2017629478C143998085 @default.
• W2017629478 hasConceptScore W2017629478C2776694085 @default.
• W2017629478 hasConceptScore W2017629478C2777472916 @default.
• W2017629478 hasConceptScore W2017629478C2777909004 @default.
• W2017629478 hasConceptScore W2017629478C2778019345 @default.
• W2017629478 hasConceptScore W2017629478C2778496288 @default.
• W2017629478 hasConceptScore W2017629478C2778695046 @default.
• W2017629478 hasConceptScore W2017629478C2780258809 @default.
• W2017629478 hasConceptScore W2017629478C29730261 @default.
• W2017629478 hasConceptScore W2017629478C526805850 @default.
• W2017629478 hasConceptScore W2017629478C71924100 @default.
• W2017629478 hasConceptScore W2017629478C90924648 @default.
• W2017629478 hasIssue "5" @default.
• W2017629478 hasLocation W20176294781 @default.
• W2017629478 hasLocation W20176294782 @default.

• next